Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
1.180
+0.020 (1.72%)
Jan 28, 2026, 12:06 PM EST - Market open
Ernexa Therapeutics Revenue
Ernexa Therapeutics had revenue of $1,000.00 in the twelve months ending September 30, 2025, down -99.83% year-over-year. In the year 2024, Ernexa Therapeutics had annual revenue of $582.00K with 755.88% growth.
Revenue (ttm)
$1,000.00
Revenue Growth
-99.83%
P/S Ratio
9,104.71
Revenue / Employee
$167
Employees
6
Market Cap
9.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 582.00K | 514.00K | 755.88% |
| Dec 31, 2023 | 68.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 24.06M | 194.00K | 0.81% |
| Dec 31, 2011 | 23.87M | -1.44M | -5.69% |
| Dec 31, 2010 | 25.31M | -505.00K | -1.96% |
| Dec 31, 2009 | 25.81M | -1.68M | -6.12% |
| Dec 31, 2008 | 27.50M | -3.05M | -9.97% |
| Dec 31, 2007 | 30.54M | -2.44M | -7.41% |
| Dec 31, 2006 | 32.99M | 2.24M | 7.27% |
| Dec 31, 2005 | 30.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evogene | 8.02M |
| XTL Biopharmaceuticals | 968.00K |
| SeaStar Medical Holding | 881.00K |
| BioRestorative Therapies | 383.40K |
| Pulmatrix | 3.00K |
ERNA News
- 1 day ago - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program - GlobeNewsWire
- 22 days ago - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D. - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics to Present at Oxford Global's Cell 2025 - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials - GlobeNewsWire
- 2 months ago - Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform - GlobeNewsWire